Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.67 USD | -1.76% | 0.00% | -42.32% |
Apr. 11 | BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target | MT |
Apr. 02 | HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating | MT |
Financials (USD)
Sales 2024 * | 16.93M | Sales 2025 * | 13.83M | Capitalization | 70.62M |
---|---|---|---|---|---|
Net income 2024 * | -58M | Net income 2025 * | -69M | EV / Sales 2024 * | 4.17 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.11 x |
P/E ratio 2024 * |
-1.32
x | P/E ratio 2025 * |
-1.27
x | Employees | 107 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.27% |
1 day | -9.09% | ||
Current month | -25.11% | ||
1 month | -30.33% | ||
3 months | -28.27% | ||
6 months | -38.63% | ||
Current year | -41.98% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 34 | 15-12-31 | |
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Richard Morris
DFI | Director of Finance/CFO | 51 | 21-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Sanford Zweifach
CHM | Chairman | 68 | 21-10-31 |
Director/Board Member | 66 | 22-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 1.69 | -0.59% | 16 798 |
24-04-23 | 1.7 | -9.09% | 135,661 |
24-04-22 | 1.87 | +14.72% | 144,126 |
24-04-19 | 1.63 | -4.68% | 257,375 |
24-04-18 | 1.71 | +1.18% | 174,528 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.98% | 70.62M | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+1.66% | 22.19B | |
-16.16% | 21.33B | |
-6.82% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- CARM Stock